Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Shire's Ornskov: The Modest Pediatrician With Fierce Corporate Ambition

Dec 21 2016

• By Eleanor Malone

Flemming Ornskov — Flemming Ornskov, CEO of Shire • Source: Shire

Related Content

Burying Shire deal, AbbVie's Gonzalez slams US Treasury

Oct 21 2014

Shire punts $160m on second eye care firm SARcode

Mar 25 2013

Shire to pay $4.2bn for rare disease firm ViroPharma

Nov 11 2013

Shire tops Q1 estimates and raises forecast

May 02 2014

Shire buys repurposed Pfizer/Sanofi drugs through $260m Lumena acquisition

May 12 2014

Ornskov OK With Cinryze 'Cannibalization' As Shire Buys Dyax (And Keeps Baxalta Guessing)

Nov 03 2015

Shire Uses Foresight to Expand in Ophthalmology

Aug 04 2015

Shire paying $5.2bn for rare disease specialist NPS

Jan 12 2015

Shire acquires Meritage for potential $245m

Feb 25 2015

Shire buys Premacure for infant eye treatment

Mar 13 2013

Shire & Baxalta Seal The Deal

May 27 2016

Additional Topics

Leadership Business Strategies Rare Diseases Companies Commercial BioPharmaceutical

More from Leadership

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window